MedPath

Multicentric trial on the effectiveness of shortened post-infusion scalp cooling times in the prevention of docetaxel-induced hair loss.

Completed
Conditions
chemotherapy-induced hair loss(Dutch: haarverlies door chemotherapie)
Registration Number
NL-OMON27012
Lead Sponsor
Comprehensive Cancer Center South (IKZ), Eindhoven, The Netherlands
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
100
Inclusion Criteria

1. Intravenous administered docetaxel-regimens at 3-weekly intervals;

2. Age 18 years or more;

Exclusion Criteria

1. TAC chemotherapy;

2. Sequential docetaxel following FEC or AC chemotherapy;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Proportion of patients not in need of wig or head cover.
Secondary Outcome Measures
NameTimeMethod
1. Impact of prior chemotherapy or hormonal therapy and liver or kidney function disorders on the result of scalp cooling;<br /><br>2. The amount and pattern of hair loss;<br /><br>3. Quality of hair during scalp cooling;<br /> <br>4. Reasons to stop scalp cooling.
© Copyright 2025. All Rights Reserved by MedPath